Anika Therapeutics plans to release Q1 2025 financial results on May 9, followed by a conference call.
Quiver AI Summary
Anika Therapeutics, Inc. announced that it will release its first quarter 2025 financial results on May 9, 2025, before market opening, followed by a conference call at 8:30 a.m. ET to discuss the results and business highlights. Interested parties can join the call through specified toll-free and international numbers using a conference ID. A live audio webcast and presentation materials will also be available on Anika's website, along with an archived version post-call. Anika is focused on joint preservation and early intervention in orthopedics, utilizing its expertise in hyaluronic acid and implant solutions to provide minimally invasive products for pain management and regenerative solutions. Its headquarters are located outside Boston, Massachusetts.
Potential Positives
- Anika Therapeutics has scheduled the release of its first quarter 2025 financial results, indicating transparency and communication with investors.
- The company will follow the financial results with a conference call to discuss highlights, which can enhance investor engagement and confidence.
- The availability of an audio webcast and presentation materials promotes accessibility to information for stakeholders.
Potential Negatives
- None
FAQ
When will Anika Therapeutics announce its Q1 2025 financial results?
Anika Therapeutics will announce its Q1 2025 financial results on May 9, 2025.
How can I join the Anika Therapeutics conference call?
The conference call can be joined by dialing 1-800-717-1738 (toll-free) or 1-646-307-1865 (international).
What time is the Anika Therapeutics conference call scheduled?
The conference call is scheduled for 8:30 a.m. ET on May 9, 2025.
Where can I access the Anika conference call webcast?
The live audio webcast will be available in the Investor Relations section of Anika's website.
What is the focus of Anika Therapeutics?
Anika focuses on joint preservation and early intervention orthopedic care, specializing in Osteoarthritis Pain Management and Regenerative Solutions.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ANIK Hedge Fund Activity
We have seen 52 institutional investors add shares of $ANIK stock to their portfolio, and 65 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALTA FUNDAMENTAL ADVISERS LLC added 404,350 shares (+136.6%) to their portfolio in Q4 2024, for an estimated $6,655,601
- MORGAN STANLEY removed 263,799 shares (-58.2%) from their portfolio in Q4 2024, for an estimated $4,342,131
- BLACKROCK, INC. removed 206,725 shares (-11.7%) from their portfolio in Q4 2024, for an estimated $3,402,693
- FRANKLIN RESOURCES INC removed 133,410 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $2,195,928
- JACOBS LEVY EQUITY MANAGEMENT, INC added 118,976 shares (+inf%) to their portfolio in Q4 2024, for an estimated $1,958,344
- SEGALL BRYANT & HAMILL, LLC removed 108,799 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,790,831
- TRIGRAN INVESTMENTS, INC. removed 102,682 shares (-4.8%) from their portfolio in Q4 2024, for an estimated $1,690,145
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
BEDFORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter 2025 financial results before the opening of the market on Friday, May 9, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.
The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 63463. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website, www.anika.com . The call will be archived and accessible on the same website shortly after its conclusion.
About Anika
Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management and Regenerative Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com .
ANIKA, ANIKA THERAPEUTICS and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.
For Investor Inquiries:
Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Director, Corporate Development and Investor Relations
[email protected]
